DekaBank Deutsche Girozentrale Has $24.72 Million Position in Agilent Technologies, Inc. (NYSE:A)

DekaBank Deutsche Girozentrale reduced its holdings in Agilent Technologies, Inc. (NYSE:A) by 36.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 168,546 shares of the medical research company’s stock after selling 98,294 shares during the quarter. DekaBank Deutsche Girozentrale owned about 0.06% of Agilent Technologies worth $24,716,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in Agilent Technologies by 18.2% during the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock worth $4,348,471,000 after buying an additional 4,605,228 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Agilent Technologies by 19.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 13,246,489 shares of the medical research company’s stock valued at $1,841,659,000 after purchasing an additional 2,170,219 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Agilent Technologies by 13.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock valued at $1,242,956,000 after purchasing an additional 1,042,926 shares in the last quarter. Norges Bank acquired a new stake in Agilent Technologies during the fourth quarter valued at approximately $509,904,000. Finally, Nordea Investment Management AB boosted its holdings in Agilent Technologies by 4.4% during the first quarter. Nordea Investment Management AB now owns 2,783,238 shares of the medical research company’s stock valued at $406,715,000 after purchasing an additional 116,822 shares in the last quarter. 87.42% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Agilent Technologies

In related news, SVP Dominique Grau sold 15,000 shares of the company’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the transaction, the senior vice president now owns 49,486 shares in the company, valued at approximately $6,595,494.08. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $140.00, for a total value of $274,120.00. Following the completion of the sale, the chief executive officer now owns 26,076 shares of the company’s stock, valued at approximately $3,650,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the sale, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders have sold 18,916 shares of company stock worth $2,527,860 in the last ninety days. Insiders own 0.33% of the company’s stock.

Agilent Technologies Stock Down 2.7 %

Shares of A stock traded down $3.82 on Friday, hitting $139.04. 2,298,354 shares of the stock were exchanged, compared to its average volume of 1,725,145. The business has a 50-day moving average of $133.32 and a 200 day moving average of $137.92. Agilent Technologies, Inc. has a fifty-two week low of $96.80 and a fifty-two week high of $155.35. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34. The firm has a market capitalization of $40.57 billion, a P/E ratio of 32.87, a price-to-earnings-growth ratio of 4.86 and a beta of 1.05.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.19 by $0.03. Agilent Technologies had a return on equity of 26.25% and a net margin of 18.84%. The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. During the same period in the prior year, the firm posted $1.27 earnings per share. The business’s quarterly revenue was down 8.4% compared to the same quarter last year. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 24th. Stockholders of record on Tuesday, July 2nd were paid a dividend of $0.236 per share. The ex-dividend date was Tuesday, July 2nd. This represents a $0.94 annualized dividend and a dividend yield of 0.68%. Agilent Technologies’s dividend payout ratio is presently 22.22%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on A shares. Barclays decreased their price objective on Agilent Technologies from $135.00 to $125.00 and set an “underweight” rating on the stock in a report on Friday, May 31st. Wolfe Research cut shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. Jefferies Financial Group reiterated a “hold” rating and issued a $135.00 target price (down previously from $152.00) on shares of Agilent Technologies in a research note on Monday, June 3rd. Evercore ISI lifted their target price on shares of Agilent Technologies from $126.00 to $130.00 and gave the company an “in-line” rating in a research note on Tuesday, July 2nd. Finally, Citigroup upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and lifted their target price for the company from $135.00 to $150.00 in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.06.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.